What is Dimension Inx?
Dimension Inx operates at the intersection of advanced materials science and regenerative medicine. The company specializes in biofabrication, utilizing its unique 3D-Painting technology to create materials that are not only versatile and manufacturable but also economically viable for widespread clinical adoption. By focusing on the fundamental architecture of human tissue, the firm provides surgeons and medical device manufacturers with the tools necessary to address complex diseases and physical debilitations. Their market position is defined by a commitment to high-precision engineering, enabling the development of next-generation medical products that offer superior biocompatibility and functional integration compared to traditional synthetic alternatives.
How much funding has Dimension Inx raised?
Dimension Inx has raised a total of $15.2M across 3 funding rounds:
Unspecified
$35K
Angel/Seed
$3.2M
Series A
$12M
Unspecified (2019): $35K, investors not publicly disclosed
Angel/Seed (2020): $3.2M led by KdT Ventures,, Better Ventures, and Rise of the Rest Seed Fund
Series A (2023): $12M supported by Prime Movers Lab and KdT Ventures
Key Investors in Dimension Inx
Prime Movers Lab
Prime Movers Lab is a venture capital firm that focuses on funding breakthrough scientific startups aimed at transforming industries and improving lives.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials.
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy.
What's next for Dimension Inx?
With the successful closure of its recent financing, Dimension Inx is entering a critical phase of operational scaling and strategic partnership expansion. The company is expected to prioritize the optimization of its manufacturing infrastructure to meet the rigorous demands of clinical trials and regulatory approval processes. Furthermore, the firm will likely deepen its collaborative efforts with leading medical institutions to validate its 3D-Painting platform across a broader spectrum of therapeutic applications. As the biofabrication landscape matures, Dimension Inx is strategically positioned to capture significant market share by addressing the unmet needs of patients requiring advanced regenerative therapies, ultimately aiming to establish its technology as the industry benchmark for tissue repair and replacement.
See full Dimension Inx company page
